The Center for Neurologic Study, a non profit 501C3 corporation, was founded in 1979 with the intent of helping patients and families who have been affected by incurable neurologic diseases, such as amyotropic lateral schlerosis (ALS). To accomplish this, we focus on experimental treatment and patient/family support and education. Along with others, CNS was instrumental in the development of Interferon as a treatment modality. This is now one of the standard therapies for multiple sclerosis. Furthermore, CNS has been a leader in an area now referred to as Translational Medicine; for example, the Center was the first to test a growth factor as a potential treatment for ALS.
Currently, we are working at the forefront of neurological therapies, through collaborations with biotech companies and universities, in an effort to develop cutting-edge treatments for neurologic disorders. Most recently, we have been involved with the development of antisense molecules that could represent a major opportunity to treat heritable diseases of the nervous system, such as familial amyotrophic lateral sclerosis and Huntingtons disease. Recently, this work was recognized by the ALS Association, awarding Dr. Don Cleveland/UCSD, Frank Bennett/Isis Pharmaceuticals, and Dr. Richard Smith/CNS with an Essey award (see News).
The seminal discovery of DMQ at CNS resulted in the award of 5 U.S. patents. This drug combination was ultimately formulated by Avanir Pharmaceutical Corporation, leading to a product now known as Nuedexta. In clinical trials, this drug was demonstrated to be highly effective for the treatment of emotional lability that occurs in association with neurological conditions, including ALS and multiple sclerosis. In October 2010, Nuedexta had been approved by the Food and Drug Administration for sale in the United States, and in 2013, it was approved in the European Union. Currently, Nuedexta being tested for its effects on behavior in those with Alzheimer's disease, and the ALS association has awarded CNS a grant to study the effect of the drug on speech and swallowing in patients affected by ALS. This study was conducted at 7 academic centers, with the Northeast ALS consortium (NEALS) managing the trial.
This website is the latest in a long-standing effort to provide patient/family education and support. But going back, beginning in 1979, CNS sponsored one of the first neurologically-based educational programs. Individual counseling is available to patients who visit CNS, and through our website, we hope to provide useful information. In special circumstances, CNS will provide online counseling to patients.
Our success is due in part to the support we have received from individuals, corporations and foundations. We welcome the opportunity to discuss how your support will advance the treatment of presently incurable diseases such as Amyotrophic Lateral Sclerosis and kindred disorders.